Stocks · News reference
Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked TCE development candidates targeting selected solid tumor-associated
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $123 to $126.
Filed: 2026-10-14 AccNo: 0001628280-26-065826 Size: 244 KB Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits